$1.05
-0.035-3.21%
Últ. Act.: Oct 7, 12:48 PM
$1.10
0.010.92%
MaxCyte (MXCT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
MaxCyte (MXCT) publicó su última previsión de agosto 12, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $30M - $32M para el período.
En comparación con la previsión anterior, MaxCyte mantenido redujo su previsión de ingresos desde un rango anterior de $30M - $32M.
MaxCyte ha emitido 26 actualizaciones de orientación entre el marzo 6, 2023 y el agosto 12, 2026. During this period, the company raised its outlook 6 times and lowered it 12 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.10 | $-0.09 | $-0.08 | $-0.10 |
| Actual | $-0.08 | $-0.04 | $-0.09 | $-0.12 |
| Surprise | +20.0% | +55.6% | -12.5% | -20.0% |
| Revenue | ||||
| Estimate | $6.5M | $7.3M | $9.2M | $8.9M |
| Actual | $7.3M | $9.7M | $7.3M | $6.8M |
| Surprise | +12.3% | +32.0% | -20.3% | -23.4% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.08 | $-0.07 | $-0.08 |
| Revenue | |||
| Consensus | $7.0M | $7.4M | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.08 | $-0.10 | 20.0 % |
| Q1 | May 12, 2026 | $-0.04 | $-0.09 | 55.6 % |
| Q4 | Mar 24, 2026 | $-0.09 | $-0.08 | -12.5 % |
| Q3 | Nov 12, 2025 | $-0.12 | $-0.10 | -20.0 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $7.27M | $6.47M | 12.3 % |
| Q1 | May 12, 2026 | $9.65M | $7.31M | 32.0 % |
| Q4 | Mar 24, 2026 | $7.30M | $9.16M | -20.3 % |
| Q3 | Nov 12, 2025 | $6.83M | $8.91M | -23.4 % |